Company Overview - Bristol Myers Squibb is one of the world's largest pharmaceutical companies, known for its long and successful track record in a highly competitive sector with high drug development costs [2] - The company is currently focusing on cardiovascular, cancer, and immune-related medicines, which are significant healthcare opportunities, despite the market's current fascination with GLP-1 weight-loss drugs [4] Financial Performance - The stock is approximately 25% below its late 2022 highs, presenting a potential recovery opportunity alongside a dividend yield of 4%, which is above the average pharmaceutical stock yield of 1.7% [5] - The payout ratio for dividends is around 70%, indicating a sustainable dividend policy, as the company has a history of regularly increasing dividends and maintaining them during tough times [5] - Key financial metrics include a market cap of $127 billion, a gross margin of 65.89%, and a current stock price of $62.37, with a day's range of $61.18 to $62.67 [6][7] Patent and Product Pipeline - Bristol Myers Squibb's Opdivo cancer drug is set to lose patent protection in 2028, raising investor concerns; however, the company is exploring alternative delivery methods to potentially extend patent protections [7] - The company has a pipeline of other drugs in development, demonstrating its ability to manage patent expirations, which are a normal aspect of the pharmaceutical business [8] Investment Opportunity - The current market conditions present an opportunity to invest in an out-of-favor stock with a relatively high yield, allowing for potential growth through dividend reinvestment [9] - While Bristol Myers Squibb should not be the sole investment, it can serve as a strong foundation for a diversified portfolio, enabling investors to take on more risk in other areas [9]

Even with a Medicare Part D plan, prescription drug costs can take a toll on seniors' finances, especially those living on a fixed income. Fortunately for some, the government has negotiated prices on 10 popular prescription drugs for 2026.Here's a closer look at which drugs are covered and how much you could save on these medications this year. The 10 negotiated Medicare drugs for 2026The following table breaks down the 10 drugs the government negotiated prices on, the agreed-upon price for a 30-day supply ...

Core Viewpoint - Novartis AG has reached a confidential settlement with the family of Henrietta Lacks regarding the unauthorized use of her cells in medical research, marking a significant resolution in the ongoing legal matters surrounding the HeLa cell line [1][2]. Settlement Details - The settlement was reached outside of court, with both parties confirming the arrangement but not disclosing financial terms. A joint statement expressed satisfaction with the private resolution [2]. - The lawsuit was filed nearly 70 years after Lacks' death, with her family arguing that companies profited from cells taken without consent. The estate has pursued multiple legal actions against pharmaceutical firms [2]. Background on HeLa Cells - In 1951, a tissue sample was taken from Henrietta Lacks during cancer treatment at Johns Hopkins Hospital without her knowledge. Her cells, known as HeLa cells, were unique in that they could multiply indefinitely in laboratory conditions [3]. - HeLa cells have significantly advanced research in vaccines and disease studies globally, contributing to breakthroughs in polio, HIV, and cancer research, as recognized by the World Health Organization [3]. Family's Experience - Henrietta Lacks passed away at the age of 31, shortly after her diagnosis. Her family remained unaware of the extensive use of her cells for decades and did not receive any compensation during the commercialization of the HeLa cell line [4]. Prior Legal Actions - In 2023, Lacks' family settled with Thermo Fisher Scientific Inc. under undisclosed terms, while additional lawsuits against other pharmaceutical companies are still ongoing. Attorney Ben Crump stated that the recent agreement provides long-overdue accountability [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success and recognition in the field [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Ultragenyx's management provided misleading information regarding the efficacy of setrusumab (UX 143) in reducing fracture rates in patients with Osteogenesis Imperfecta [5]. - It is claimed that while setrusumab increases bone density, this does not correlate with a decrease in fracture rates, and the studies were less likely to demonstrate the claimed results than management suggested [6]. - The misleading statements allegedly led to investors purchasing shares at inflated prices, resulting in damages when the true information became public [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][7]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder [5]. - Defendants reportedly made positive assertions about fasedienol's trial success based on previous positive results, while concealing material adverse facts about the Phase 3 PALISADE-3 trial [6].

Core Insights - Viatris Inc. (NASDAQ: VTRS) is recognized as one of the 13 Best March Dividend Stocks to Buy [1] - UBS has raised its price target for Viatris from $18 to $20, maintaining a Buy rating, citing the company's achievement of Q4 cost-saving goals and positive FY26 guidance [2] - The company reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion for Q4 2025, indicating strong financial performance [3] Financial Performance - Viatris achieved total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion in Q4 2025, reflecting the overall strength of the business [3] - The company returned over $1 billion to shareholders through dividends and share repurchases during the year [4] Growth Outlook - Viatris expects to generate approximately $650 million in gross cost savings over three years, with up to $250 million reinvested into growth initiatives [5] - The company is preparing for a potential FDA reinspection of its Indore facility, implementing operational redundancies to ensure continuity and stability [5] Pipeline Progress - Five Phase III studies have delivered positive results, marking an important milestone for the company [4] - Enrollment in key programs, including cenerimod and selatogrel, is progressing and expected to be completed in 2026 [4] Strategic Initiatives - The completion of 60 regional transactions, including the acquisition of Aculys Pharma in Japan, is part of Viatris' broader strategic plan [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [4] - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [4] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements made by the defendants [4]

We came across a bullish thesis on Halozyme Therapeutics, Inc. on 24K Research’s Substack. In this article, we will summarize the bulls’ thesis on HALO. Halozyme Therapeutics, Inc.'s share was trading at $70.98 as of February 20th. HALO’s trailing and forward P/E were 16.41 and 8.19, respectively according to Yahoo Finance. Morgan Stanley Lifted GE HealthCare Target to $80 in Late October, Citing Strong Orders and Backlog Wichy/Shutterstock.com Halozyme Therapeutics Inc (HALO), based in San Diego, Calif ...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients With Earlier-Stage RCC. ...

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC Patients. ...